Vaccine for inducing an improved immune reaction
The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib ( Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
1. A method for inducing immunity to an antigen in a subject comprising administering to the subject a pharmaceutically effective amount of a vaccine composition comprising: (a) a pathogen-derived antigen selected from a group consisting of influenza virus antigen, Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, Varicella-zoster virus antigen which is live attenuated Varicella-zoster virus, inactivated attenuated Varicella-zoster virus, gpI or gpII, HAV (Hepatitis A virus) antigen, HCV (Hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, HSV (Herpes simplex virus) antigen, Hib ( Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheria antigen, Bordetella pertussis antigen and Clostridium tetani antigen; (b) a deacylated non-toxic LOS (Lipooligosaccharide) having a molecular weight in a range of 2,000-4,000Da, obtained by deacylation of lipid A of lipopolysaccharide isolated from Escherichia coli ; and (c) a pharmaceutically acceptable carrier, with the proviso that the vaccine composition does not include an oligodeoxynucleotide (ODN) as an adjuvant.
2. The method according to claim 1 , wherein Mycobacterium tuberculosis antigen is at least one antigen selected from a group consisting of 65 kD heat shock protein (HSP65), antigen 85A (Ag85A), antigen 85B, antigen 85C, ESAT-6, Des protein, MPT32, MPT51, MPT63, MPT64, HspX and Phosphate binding protein 1.
3. The method according to claim 2 , wherein Mycobacterium tuberculosis antigen is at least one antigen selected from a group consisting of antigen 85A (Ag85A), ESAT-6, HspX and Phosphate binding protein 1.
4. The method according to claim 1 , wherein influenza virus antigen is envelope glycoprotein HA or NA.
5. The method according to claim 4 , wherein influenza virus antigen is envelope glycoprotein HA.
6. The method according to claim 1 , wherein the non-toxic LOS is detoxificated by deacylation of lipid A via alkaline treatment to LPS (lipopolysaccharide).
7. The method according to claim 1 , wherein the pharmaceutical composition further comprises an immunoadjuvant which is: a Group II element selected from the group consisting of Mg, Ca, Sr, Ba and Ra; a Group IV element selected from the group consisting of Ti, Zr, Hf and Rf; or an aluminium salt or a hydrate thereof.